首页> 外文期刊>Drugs: International Journal of Current Therapeutics and Applied Pharmacology Reviews, Featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts >Coronary artery vasomotion and post-stenotic coronary artery blood flow after intracoronary lacidipine in patients with ischaemic heart disease: a pilot study.
【24h】

Coronary artery vasomotion and post-stenotic coronary artery blood flow after intracoronary lacidipine in patients with ischaemic heart disease: a pilot study.

机译:缺血性心脏病患者冠状动脉内lacidipine术后的冠状动脉血管舒张和狭窄后冠状动脉血流量:一项前瞻性研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The calcium antagonist lacidipine has been shown to be highly vasoselective and to improve myocardial perfusion in hypertensive patients. However, its effects on coronary artery vasomotility and on post-stenotic coronary flow reserve in patients with atherosclerotic heart disease are unknown. OBJECTIVES: This study was designed to investigate the acute direct effects of repeated infusions of lacidipine on epicardial coronary artery vasomotion and on post-stenotic coronary artery blood flow in patients with stable angina pectoris and angiographic evidence of coronary heart disease. METHODS: In 8 patients with stable angina and moderate to severe stenosis of the left coronary artery, measurements of epicardial dimensions (quantitative angiography) and of coronary blood flow (Doppler guidewire) distal to a stenosis were performed at baseline and after 3 repeated intracoronary boluses of 12 microg of lacidipine. Results were compared with those obtained after 10 mg of intracoronary papaverine. RESULTS: The intracoronary administration of lacidipine was well tolerated, without any adverse effects. Lacidipine significantly increased the minimal luminal diameter of the lesion (peak relative increase of 43.7%), without significant changes in heart rate and systolic aortic pressure. Intracoronary lacidipine caused a dose-dependent increase in coronary flow reserve. Maximal vasodilatory effects were equivalent to those obtained with intracoronary papaverine. CONCLUSIONS: These results suggest that lacidipine acts directly as a potent vasodilator in stenotic epicardial vessels and improves myocardial perfusion distal to a moderately severe stenosis in patients with stable angina.
机译:背景:钙拮抗剂拉西地平已被证明具有高度的血管选择性,并能改善高血压患者的心肌灌注。然而,它对动脉粥样硬化性心脏病患者冠状动脉血管扩张和狭窄后冠状动脉血流储备的影响尚不清楚。目的:本研究旨在研究反复输注拉地平对稳定型心绞痛和冠心病患者的冠心病心外膜冠状动脉血管运动和狭窄后冠状动脉血流的急性直接影响。方法:在基线时以及在重复3次冠状动脉内大剂量治疗后,对8例稳定型心绞痛和左冠状动脉中度至重度狭窄的患者进行了测量,在狭窄的远端进行了心外膜尺寸(定量血管造影)和冠状动脉血流测量(多普勒导丝)。 12微克的拉地平。将结果与10 mg冠状动脉内罂粟碱给药后的结果进行比较。结果:拉西地平冠状动脉内给药耐受性良好,无任何不良反应。拉西地平显着增加病变的最小管腔直径(峰值相对增加43.7%),而心率和收缩主动脉压无明显变化。冠状动脉内拉西地平引起冠状动脉血流储备的剂量依赖性增加。最大血管舒张作用等同于使用冠状动脉罂粟碱获得的血管舒张作用。结论:这些结果表明,在稳定型心绞痛患者中,拉西地平可直接充当狭窄心外膜血管的有效血管舒张剂,并改善中重度狭窄患者的心肌灌注。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号